Description
Bracco
MultiHance® (gadobenate dimeglumine) injection, 529 mg/mL is a gadolinium-based contrast agent indicated for intravenous use in:1
- Magnetic resonance imaging (MRI) of the central nervous system (CNS) in adults and pediatric patients (including term neonates), to visualize lesions with abnormal blood-brain barrier or abnormal vascularity of the brain, spine, and associated tissues and
- Magnetic resonance angiography (MRA) to evaluate adults with known or suspected renal or aorto-ilio-femoral occlusive vascular disease.
1. MultiHance (gadobenate dimeglumine) injection, 529 mg/mL full Prescribing Information. Monroe Twp., NJ: Bracco Diagnostics Inc. August 2018.
MultiHance® (gadobenate dimeglumine) injection, 529 mg/mL is a stable, linear, ionic gadolinium-based contrast agent (GBCA) known to have high thermodynamic and conditional stability.1,2 Based on its transient interactions with serum proteins, MultiHance (gadobenate dimeglumine) injection, 529 mg/mL has greater relaxivity than the other GBCA approved for CNS imaging.1,3,4,5
In multiple clinical studies with intra-individual comparisons, MultiHance (gadobenate dimeglumine) injection, 529 mg/mL demonstrated significantly improved visualization and contrast enhancement of central nervous system (CNS) lesions when compared with Gadavist®, 6 Dotarem®, 7 OmniscanTM 8 and Magnevist®.9
MultiHance (gadobenate dimeglumine) injection, 529 mg/mL was preferred among readers for all 5 qualitative endpoints:6-9
- Global diagnostic preference
- Lesion border delineation
- Definition of disease extent
- Visualization of lesion internal morphology
- Lesion contrast enhancement
MultiHance (gadobenate dimeglumine) injection, 529 mg/mL demonstrated excellent diagnostic performance in magnetic resonance angiography (MRA) to evaluate adults with known or suspected renal or aorto-ilio-femoral occlusive vascular disease.1,10-13
